Management of Advanced and Relapsed/Refractory Extra-Nodal Natural Killer T-Cell Lymphoma (ENKL): An Analysis of Stem Cell Transplant and Chemotherapy Outcomes

Extra-nodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoma representing approximately 5-10% of T-cell non-Hodgkin lymphomas diagnosed in the United States each year.1, 2 ENKL is universally associated with Epstein-Barr virus (EBV) infection, and is more frequent in Asian, Central American and South American populations, where it constitutes 5-15% of all lymphomas.3-5 Patients with advanced stage ENKL (stage III-IV) and relapsed/refractory early stage disease are treated with systemic chemotherapy with or without radiotherapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Conclusions: IAC is effective as primary therapy for unilateral group B, C, D, and E retinoblastoma. IvitC is an important adjuvant therapy to achieve comparable globe salvage rates for group D and E eyes with persistent active vitreous seeds.Ocul Oncol Pathol
Source: Ocular Oncology and Pathology - Category: Opthalmology Source Type: research
In recent years, researchers working on forms of telomerase gene therapy have produced evidence to show that increased levels and activity of telomerase does not raise cancer risk in mice. The open access paper and publicity materials noted below report the latest example. Extra telomerase increases the sort of activities that are beneficial in the context of improved regenerative capacity, but might be thought to raise the risk of cancer when they take place in the damaged environment of old tissue. This means more stem cell activity, more cellular replication, and so forth. Somatic cells are limited in the degree ...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
Publication date: Available online 27 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Francine M. Foss, Terri L. Parker, Michael Girardi, Anlong LiSummaryCutaneous T-cell lymphomas (CTCL) are rare, heterogeneous non-Hodgkin lymphomas with poor prognoses. Treatment options for CTCL are limited by the their efficacy and tolerability profile. Pralatrexate has demonstrated efficacy in T-cell lymphomas, however dose-modifying adverse events, such as mucositis have occurred. We retrospectively reviewed clinical responses and toxicity in 27 CTCL patients treated with pralatrexate at doses ranging from 10-30mg/...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Our results suggest that achievement of a CR is imperative in patients with advanced ENKL, and is desirable for any patient for whom auto-SCT is utilized. SMILE-based chemotherapy appeared effective in attaining a CR, and was also an effective salvage regimen. For patients attaining a first CR, auto-SCT should be strongly considered, but should definitely be utilized in patients attaining CR2. For patients with refractory disease, allo-SCT can be considered in a selected group of patients. Micro-Abstract We present a cohort of primarily non-Asian patients with advanced stage and relapsed/refractory ENKL. Our res...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusions PET/CT compared to CECT allowed a more accurate staging and after therapy pointed out minimal residual disease in 22% of CECT negative pts and complete remission in 36% of CECT positive pts.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: MTA I: Leukemia/Lymphoma/Myeloma Posters Source Type: research
Conclusion Most PTCL relapses were detected before planned SI, and most patients had symptoms with relapse. Only 3 patients (5.2%) were completely asymptomatic at relapse, suggesting a limited utility of routine imaging for detecting PTCL relapses. Micro-Abstract Data from aggressive lymphoma such as diffuse large B-cell lymphoma and Hodgkin lymphoma suggest a limited utility of surveillance imaging (SI) after achieving first complete remission. The present study of patients with peripheral T-cell lymphoma showed similar data, with most relapses detected apart from planned SI and associated with abnormal symptoms or signs...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusions The majority of PTCL relapses were detected prior to planned SI and most patients had symptoms on relapse. Only 3 patients (5.2%) were completely asymptomatic at relapse suggesting a limited utility of routine imaging in detecting PTCL relapses. Teaser Data from aggressive lymphoma such as diffuse large B-cell lymphoma and Hodgkin lymphoma suggest a limited utility of surveillance imaging (SI) after achieving first complete remission. This study in patients with peripheral T-cell lymphoma (PTCL) is similar in that it showed that most relapses are detected apart from planned SI and are associated with abnormal s...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion SS is a rare and aggressive type of CTCL that is refractory to current therapies. We report that CRs can be achieved in 3 methods: combined immunomodulatory therapy, targeted biologic agents, or total skin electron beams followed by nonablative allogeneic SCT. Micro-Abstract Sézary syndrome is a rare leukemic variant of primary cutaneous non-Hodgkin lymphomas that is difficult to treat. We report on 18 patients who had achieved long-term complete remission or response (CR) of ≥ 1 year and 7 patients who had achieved durable responses (DR) with subsequent relapse. The choices of therapy, including...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 3 January 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Ranjit Kumar Chaudhary , Vijaya Raj Bhatt , Julie M. Vose Extranodal natural killer/T-cell lymphoma, nasal type (NKTL) is an uncommon aggressive subtype of non-Hodgkin lymphoma, which is significantly more common in East Asia and Latin America. Three-quarters of patients present with stage I/II disease, and half of patients have a low-risk International Prognostic Index score. Although additional factors including natural killer/T-cell lymphoma prognostic index and peripheral blood Epstein-Barr virus load influence ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Chemotherapy | Hematology | Hodgkin's Disease | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | T-cell Lymphoma | Transplants | USA Health